Impact of whole-body MRI and FDG-PET on staging and assessment of therapy response in a patient with Ewing sarcoma.
In patients with Ewing sarcoma, precise staging is not only crucial for the therapeutic regimen but also for a reliable evaluation of response to therapy. We report on a 15-year-old girl with metastatic spread of a Ewing sarcoma who, apart from conventional staging by bone scan, chest X-ray and CT, was subsidiary examined by FDG-PET and whole-body MRI before and after chemotherapy. Both modalities detected more bone lesions than the bone scan, which led to an altered strategy for radiotherapy. Both examinations might be a great asset to stage-adjusted therapy regimens, ultimately influencing patient outcome.
Furth
C
C
Klinik für Strahlenheilkunde, Bereiche Diagnostische Radiologie und Nuklearmedizin, Charité-Universitätsmedizin, Berlin, Germany. christian.furth@charite.de
Amthauer
H
H
Denecke
T
T
Ruf
J
J
Henze
G
G
Gutberlet
M
M
D000293:Adolescent; D001859:Bone Neoplasms / Q000175:diagnosis* / Q000556:secondary / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography / Q000379:methods*; D011237:Predictive Value of Tests; D012512:Sarcoma, Ewing / Q000175:diagnosis* / Q000556:secondary / Q000628:therapy*; D012680:Sensitivity and Specificity